Cargando…

Elevated plasma levels of plasminogen activator inhibitor‐1 are associated with risk of future incident venous thromboembolism

BACKGROUND: Plasminogen activator inhibitor‐1 (PAI‐1), the main inhibitor of fibrinolysis, is frequently elevated in obesity and could potentially mediate the risk of venous thromboembolism (VTE) in obese subjects. However, whether PAI‐1 is associated with VTE remains uncertain. OBJECTIVE: To invest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frischmuth, Tobias, Hindberg, Kristian, Aukrust, Pål, Ueland, Thor, Brækkan, Sigrid K., Hansen, John‐Bjarne, Morelli, Vânia M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	THROMBOSIS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314992/ https://www.ncbi.nlm.nih.gov/pubmed/35289062 http://dx.doi.org/10.1111/jth.15701

Ejemplares similares

Joint effect of myocardial infarction and obesity on the risk of venous thromboembolism: The Tromsø Study
por: Sejrup, Joakim K., et al.
Publicado: (2022)

Impact of respiratory symptoms and oxygen saturation on the risk of incident venous thromboembolism—the Tromsø study
por: Børvik, Trond, et al.
Publicado: (2020)

Dietary intake of marine n‐3 polyunsaturated fatty acids and future risk of venous thromboembolism
por: Isaksen, Trond, et al.
Publicado: (2018)

D-Dimer Measured at Diagnosis of Venous Thromboembolism is Associated with Risk of Major Bleeding
por: Johnsen, Håkon S., et al.
Publicado: (2019)

Acute infection as a trigger for incident venous thromboembolism: Results from a population‐based case‐crossover study
por: Grimnes, Gro, et al.
Publicado: (2017)

Role of microRNAs in Venous Thromboembolism
por: Morelli, Vânia M., et al.
Publicado: (2020)

The Role of Stroke as a Trigger for Incident Venous Thromboembolism: Results from a Population-based Case-Crossover Study
por: Morelli, Vânia M., et al.
Publicado: (2019)

Atrial fibrillation, venous thromboembolism, ischemic stroke, and all‐cause mortality: The Tromsø study
por: Hald, Erin Mathiesen, et al.
Publicado: (2020)

The association between red cell distribution width and venous thromboembolism is not explained by myocardial infarction, stroke, or cancer
por: Ellingsen, Trygve S., et al.
Publicado: (2018)

Surgery As a Trigger for Incident Venous Thromboembolism: Results from a Population-Based Case-Crossover Study
por: Meknas, Dana, et al.
Publicado: (2023)

Myocardial infarction, prothrombotic genotypes, and venous thrombosis risk: The Tromsø Study
por: Sejrup, Joakim K., et al.
Publicado: (2020)

Hand grip strength and risk of incident venous thromboembolism: The Tromsø study
por: Leknessund, Oda G. R., et al.
Publicado: (2022)

Plasma procoagulant phospholipid clotting time and venous thromboembolism risk
por: Ramberg, Cathrine, et al.
Publicado: (2021)

Cancer‐associated venous thromboembolism: Incidence and features in a racially diverse population
por: Raskob, Gary E., et al.
Publicado: (2022)

Hand grip strength in venous thromboembolism: risk of recurrence and mortality
por: Leknessund, Oda G.R., et al.
Publicado: (2023)

Risk factors and predictors for venous thromboembolism in people with ischemic stroke: A systematic review
por: Tøndel, Birgitte G., et al.
Publicado: (2022)

Genetic risk and incident venous thromboembolism in middle‐aged and older adults following COVID‐19 vaccination
por: Xie, Junqing, et al.
Publicado: (2022)

Overall and abdominal obesity in relation to venous thromboembolism
por: Yuan, Shuai, et al.
Publicado: (2020)

Hematocrit and incidence of venous thromboembolism
por: Folsom, Aaron R., et al.
Publicado: (2020)

Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort
por: Gade, Inger Lise, et al.
Publicado: (2018)

Plasma lipopolysaccharide‐binding protein is a biomarker for future venous thromboembolism: Results from discovery and validation studies
por: Jensen, Søren Beck, et al.
Publicado: (2022)

Evaluation of the Khorana, PROTECHT, and 5‐SNP scores for prediction of venous thromboembolism in patients with cancer
por: Guman, Noori A. M., et al.
Publicado: (2021)

Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study
por: Crobach, Monique J. T., et al.
Publicado: (2023)

Resting heart rate and incidence of venous thromboembolism
por: Folsom, Aaron R., et al.
Publicado: (2019)

Impact of Venous Thromboembolism on the Formation and Progression of Carotid Atherosclerosis: The Tromsø Study
por: Lind, Caroline, et al.
Publicado: (2017)

Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study
por: Giustozzi, Michela, et al.
Publicado: (2021)

D‐dimer to rule out venous thromboembolism during pregnancy: A systematic review and meta‐analysis
por: Bellesini, Marta, et al.
Publicado: (2021)

Pharmacokinetic modeling and simulation support for age‐ and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism
por: Röshammar, Daniel, et al.
Publicado: (2021)

Risk of recurrence in women with venous thromboembolism related to estrogen‐containing contraceptives: Systematic review and meta‐analysis
por: Wiegers, Hanke M. G., et al.
Publicado: (2022)

Weight Change and Risk of Venous Thromboembolism: The Tromsø Study
por: Horvei, Lars Daae, et al.
Publicado: (2016)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta‐analysis
por: Mulder, Frits I., et al.
Publicado: (2020)

Awareness of venous thromboembolism among patients with cancer: Preliminary findings from a global initiative for World Thrombosis Day
por: Potere, Nicola, et al.
Publicado: (2022)

Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury: systematic review and network meta‐analysis
por: Horner, Daniel, et al.
Publicado: (2019)

Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up
por: Salisbury, Richard, et al.
Publicado: (2020)

Atherosclerotic Risk Factors and Risk of Myocardial Infarction and Venous Thromboembolism; Time-Fixed versus Time-Varying Analyses. The Tromsø Study
por: Småbrekke, Birgit, et al.
Publicado: (2016)

Galectin‐3 and venous thromboembolism incidence: the Atherosclerosis Risk in Communities (ARIC) Study
por: Fashanu, Oluwaseun E., et al.
Publicado: (2017)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement
por: Jameson, S. S., et al.
Publicado: (2014)

Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery—Systematic review and meta‐analysis
por: Presume, João, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kit6a41pb35opjhok6jrheuvnt